Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates

Nutriband Inc. (NTRB) reported a Q1 loss of $0.12 per share, a 7.69% positive surprise compared to the Zacks Consensus Estimate, but missed revenue estimates by 6.06% with $0.67 million in revenue. Despite outperforming the S&P 500 year-to-date with a 37.2% gain, the company's Zacks Rank is currently a #3 (Hold), suggesting near-term performance in line with the market; future stock movement will depend on earnings call commentary and revisions to upcoming EPS estimates of -$0.16 on $0.76 million revenue for the next quarter and -$0.56 on $14.09 million revenue for the current fiscal year.

Analysis

Nutriband Inc. (NTRB) reported a Q1 loss of $0.12 per share, which was narrower than the loss of $0.21 per share in the corresponding period last year and represented a 7.69% positive earnings surprise compared to the Zacks Consensus Estimate of a $0.13 loss. This positive surprise, however, follows a pattern of inconsistency, as the company has surpassed consensus EPS estimates only once in the last four quarters, with the prior quarter showing a -50% negative surprise. On the revenue front, Nutriband posted $0.67 million for the quarter ended April 2025, an increase from $0.41 million year-over-year, but this figure fell short of the Zacks Consensus Estimate by 6.06%. The company has notably failed to meet consensus revenue estimates over the last four quarters. Despite these mixed financial results, NTRB shares have demonstrated strong performance, gaining approximately 37.2% since the beginning of the year, significantly outpacing the S&P 500's 0.5% gain. The stock currently holds a Zacks Rank #3 (Hold), reflecting a mixed trend in estimate revisions leading up to this earnings release and suggesting an expectation of in-line market performance in the near term. Future stock movement is anticipated to heavily depend on management's commentary during the earnings call and subsequent adjustments to earnings forecasts. Current consensus estimates project a loss of $0.16 per share on $0.76 million in revenue for the upcoming quarter, and a loss of $0.56 per share on $14.09 million in revenue for the current fiscal year. Nutriband operates within the Medical - Drugs industry, which is currently ranked in the top 28% of over 250 Zacks industries, indicating a generally favorable sector environment.

Key Decisions for Investors

• Investors should closely scrutinize management's upcoming earnings call for insights into strategies to address the revenue miss and improve consistency in meeting financial targets, particularly given the recent revenue shortfall despite the EPS beat.
• Given the substantial year-to-date stock appreciation of 37.2%, it is prudent to assess whether the current valuation adequately reflects the mixed Q1 operational performance and the persistent inability to meet revenue consensus estimates.
• Monitor forthcoming revisions to earnings and revenue estimates closely, as these will be critical indicators for the stock's future trajectory and will help validate the sustainability of its current Zacks Rank #3 (Hold).
• While the company operates within a favorably ranked industry, focus on Nutriband's specific execution capabilities and its progress towards achieving its own financial projections before making new investment decisions or adjusting existing positions.